Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
- 31 January 2001
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 46 (2) , 126-133
Abstract
Background The prognosis of patients with localized prostate cancer depends on clinical stage, histological grade, and pretreatment prostate‐specific antigen (PSA). We evaluated the additional prognostic impact of serum levels of neuron‐specific enolase (NSE) and chromograninA (CgA) after curative radiotherapy and the importance of serum PSA, analyzed 3 months after irradiation. Methods From 1988 to 1995, 161 patients with localized T1‐4, pN0M0, prostate adenocarcinoma were treated with external radiation (66Gy, 2Gy/5 fractions per week). Frozen serum samples were assessed for CgA, NSE, and PSA before and 3 months after radiotherapy. CgA was analyzed in only 100 patients. NSE and CgA were determined by a immunometric assay. Total PSA was measured by a time‐resolved fluoro‐immunometric assay. Results Prior to radiotherapy CgA was elevated in 16 of 100 patients, and NSE was elevated in 33 of the 161 patients. There was no association between grade, T category or pretreatment PSA and the levels of neuroendocrine markers. Pretreatment‐elevated serum NSE, but not initial CgA, identified patients with an unfavorable prognosis. A < 50% reduction of PSA 3 months after radiotherapy was associated with decreased failure‐free 10 years urvival. Multivariate analysis demonstrated an increased risk of failure for patients with elevated pretreatment NSE and PSA values, T3 category, and decline of PSA less than 50% 3 months after radiotherapy. The presence of none or several risk factors (1–4) defined clearly separable groups. Conclusions Together with T category and pretreatment serum PSA values, serum NSE values before radiotherapy and decrease of serum PSA 3 months after radiotherapy represent easily assessable prognostic parameters in patients undergoing curative radiation treatment for prostate cancer. Prostate 46:126–133, 2001.Keywords
This publication has 33 references indexed in Scilit:
- POTENCY, CONTINENCE AND COMPLICATION RATES IN 1,870 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIESJournal of Urology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997
- Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical controlInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomyHuman Pathology, 1996
- Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostateUrology, 1996
- Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate CancerJournal of Urology, 1995
- The effect of dose on local control of prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1988
- Zur Frage der Endokrinie der menschlichen vorsteherdrüseVirchows Archiv, 1944